ADA and rheumatoid arthritis: The post hoc analysis of the CREDO-2 study presented here aimed at precisely investigating this aspect, namely, the impact of comorbidities on the efficacy and safety of olokizumab (OKZ) [10–13], a humanized monoclonal antibody (mAb) developed as an inhibitor of interleukin-6 (IL-6), and adalimumab (ADA), an anti-TNF agent, in patients with RA and an inadequate response to csDMARDs who were included in this randomized clinical trial, comparing these agents with a placebo.